Table 1.
Meningococcal protein andpolysaccharide conjugate vaccines *.
| Vaccine Product | Trade Name | Age Group | Year Licensed |
|---|---|---|---|
| Polysaccharide Conjugate (Groups A, C, W, and Y) | |||
| MenACWY-D | Menactra | 9 months–55 years | 2005 |
| MenACWY-CRM | Menveo | ≥2 months | 2010 |
| MenACWY-TT | MenQuadfi #/Nimenrix | ≥1 year/≥6 weeks | 2020/2012 |
| MenA-TT | MenAfriVac | 3 months–29 years | 2010 |
| Protein based (directed at group B) | |||
| MenB-FHbp | Trumenba | 10–25 years | 2014 |
| MenB-4C # | Bexsero | ≥2 months | 2015 |
Abbreviations: MenACWY-CRM = meningococcal groups A, C, W, and Y capsular polysaccharide-diphtheria CRM197 conjugate; -D = diphtheria toxoid conjugate; -TT = tetanus toxoid conjugate vaccine; MenB-4C = four-component meningococcal group B vaccine; MenB-FHbp = meningococcal group B bivalent factor H binding protein vaccine. # MenQuadfi is indicated for ≥2 years in the U.S. Bexsero is licensed for 10–25 years in the U.S. * Monovalent C conjugate vaccines, including Meningitec (MenC-CRM197), Menjugate (MenC-CRM197), NeisVac-C (MenC-TT), and Menitroix (MenC-TT+Hib), are still in use in some countries. Additional conjugate vaccines directed against MenAC and MenC are also available in China. Pentavalent meningococcal conjugate vaccines: MenABCWY (MenACWY-CRM-197 combined with MenB multicomponent recombinant proteins, GlaxoSmithKline), MenABCWY (bivalent FHbp-containing pentavalent vaccine, Pfizer), and MenACXWY (NmCV-5, Serum Institute of India) are in phase 3 clinical trials.